| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 57 | 2020 | 15694 | 2.070 |
Why?
|
| Integrin alpha6beta4 | 5 | 2009 | 31 | 1.460 |
Why?
|
| Sentinel Lymph Node Biopsy | 10 | 2016 | 1415 | 1.170 |
Why?
|
| Carcinoma, Ductal, Breast | 15 | 2020 | 1216 | 1.100 |
Why?
|
| Breast | 7 | 2021 | 1344 | 0.960 |
Why?
|
| Lymphatic Metastasis | 18 | 2018 | 4844 | 0.780 |
Why?
|
| Lymph Nodes | 12 | 2016 | 2967 | 0.670 |
Why?
|
| Metaplasia | 6 | 2016 | 383 | 0.660 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2012 | 674 | 0.620 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.550 |
Why?
|
| Triple Negative Breast Neoplasms | 7 | 2021 | 1215 | 0.550 |
Why?
|
| Immunohistochemistry | 22 | 2020 | 7548 | 0.540 |
Why?
|
| Hyaluronan Receptors | 3 | 2005 | 249 | 0.540 |
Why?
|
| Radiation Exposure | 1 | 2016 | 73 | 0.530 |
Why?
|
| Mammography | 10 | 2019 | 1010 | 0.520 |
Why?
|
| Iodine Radioisotopes | 1 | 2016 | 371 | 0.500 |
Why?
|
| Occupational Exposure | 1 | 2016 | 244 | 0.500 |
Why?
|
| Receptor, ErbB-2 | 10 | 2012 | 2518 | 0.470 |
Why?
|
| Carcinoma | 4 | 2013 | 2578 | 0.460 |
Why?
|
| Frozen Sections | 1 | 2013 | 105 | 0.450 |
Why?
|
| Axilla | 6 | 2018 | 902 | 0.410 |
Why?
|
| Female | 74 | 2021 | 141928 | 0.390 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 1301 | 0.390 |
Why?
|
| Integrins | 2 | 2006 | 262 | 0.380 |
Why?
|
| Mastectomy | 9 | 2018 | 1534 | 0.380 |
Why?
|
| Triage | 1 | 2012 | 252 | 0.370 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2009 | 4 | 0.350 |
Why?
|
| Biopsy, Needle | 9 | 2010 | 1363 | 0.350 |
Why?
|
| Middle Aged | 53 | 2020 | 86204 | 0.350 |
Why?
|
| BRCA1 Protein | 1 | 2012 | 493 | 0.340 |
Why?
|
| Carcinosarcoma | 2 | 2021 | 146 | 0.330 |
Why?
|
| Humans | 95 | 2021 | 261506 | 0.330 |
Why?
|
| Diagnosis, Differential | 15 | 2014 | 4744 | 0.320 |
Why?
|
| In Situ Hybridization | 3 | 2005 | 1037 | 0.320 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 177 | 0.310 |
Why?
|
| Mastectomy, Segmental | 1 | 2013 | 1026 | 0.310 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 423 | 0.300 |
Why?
|
| Carcinoma, Papillary | 2 | 2009 | 584 | 0.300 |
Why?
|
| Adult | 43 | 2019 | 77950 | 0.300 |
Why?
|
| Cell Adhesion | 8 | 2006 | 1008 | 0.300 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 354 | 0.290 |
Why?
|
| Biomarkers, Tumor | 13 | 2019 | 10331 | 0.290 |
Why?
|
| Aged | 42 | 2019 | 70117 | 0.280 |
Why?
|
| Neoplasm Metastasis | 5 | 2015 | 5112 | 0.280 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 1998 | 178 | 0.280 |
Why?
|
| Ultrasonography, Mammary | 6 | 2015 | 380 | 0.280 |
Why?
|
| Receptors, Estrogen | 6 | 2012 | 2086 | 0.270 |
Why?
|
| Gene Expression | 3 | 2016 | 3570 | 0.270 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 554 | 0.270 |
Why?
|
| Stromal Cells | 1 | 2009 | 825 | 0.260 |
Why?
|
| Receptors, Progesterone | 4 | 2012 | 1392 | 0.260 |
Why?
|
| Carcinoma, Lobular | 5 | 2020 | 611 | 0.260 |
Why?
|
| Ribosomal Proteins | 2 | 2016 | 118 | 0.260 |
Why?
|
| ErbB Receptors | 3 | 2009 | 2295 | 0.260 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2005 | 109 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2013 | 10035 | 0.240 |
Why?
|
| Carrier Proteins | 3 | 2021 | 2022 | 0.240 |
Why?
|
| Mammaglobin A | 2 | 2015 | 14 | 0.240 |
Why?
|
| Genetic Testing | 1 | 2012 | 1589 | 0.230 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 1443 | 0.230 |
Why?
|
| Neoplasm Staging | 13 | 2018 | 13658 | 0.230 |
Why?
|
| Testicular Neoplasms | 2 | 1998 | 529 | 0.220 |
Why?
|
| Monocytes | 3 | 1992 | 788 | 0.220 |
Why?
|
| Epithelial Cells | 2 | 2009 | 1818 | 0.220 |
Why?
|
| Aged, 80 and over | 22 | 2016 | 29902 | 0.220 |
Why?
|
| Fibroadenoma | 2 | 2014 | 25 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 9 | 2012 | 3981 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2011 | 436 | 0.210 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 821 | 0.210 |
Why?
|
| Crystallization | 2 | 2000 | 132 | 0.210 |
Why?
|
| Phyllodes Tumor | 2 | 2014 | 62 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2013 | 5437 | 0.200 |
Why?
|
| Sarcoma | 3 | 2012 | 1725 | 0.200 |
Why?
|
| Galectin 3 | 2 | 2016 | 138 | 0.200 |
Why?
|
| Tongue Neoplasms | 2 | 2005 | 246 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 5 | 2018 | 4975 | 0.190 |
Why?
|
| Breast Diseases | 2 | 2015 | 201 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2015 | 1678 | 0.190 |
Why?
|
| Tyrosine | 2 | 2000 | 498 | 0.180 |
Why?
|
| Parotid Diseases | 1 | 2000 | 12 | 0.180 |
Why?
|
| Glycoproteins | 2 | 2015 | 747 | 0.180 |
Why?
|
| Parotid Gland | 1 | 2000 | 112 | 0.180 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2011 | 716 | 0.180 |
Why?
|
| Microscopy, Electron | 5 | 1998 | 600 | 0.170 |
Why?
|
| Doxorubicin | 4 | 2017 | 3005 | 0.170 |
Why?
|
| Sertoli Cell Tumor | 1 | 1998 | 12 | 0.170 |
Why?
|
| Glomus Tumor | 1 | 1999 | 27 | 0.170 |
Why?
|
| Carcinoma, Basosquamous | 1 | 1998 | 12 | 0.170 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 1999 | 69 | 0.170 |
Why?
|
| Pituitary Gland | 1 | 1999 | 150 | 0.170 |
Why?
|
| Prognosis | 14 | 2020 | 21713 | 0.170 |
Why?
|
| Urethral Neoplasms | 1 | 1998 | 60 | 0.160 |
Why?
|
| Salivary Ducts | 1 | 1998 | 56 | 0.160 |
Why?
|
| Nuclear Proteins | 3 | 2021 | 3343 | 0.160 |
Why?
|
| Endothelium, Vascular | 3 | 1992 | 891 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2000 | 315 | 0.160 |
Why?
|
| Signal Transduction | 7 | 2017 | 11965 | 0.160 |
Why?
|
| Adenolymphoma | 1 | 1998 | 27 | 0.160 |
Why?
|
| Mitosis | 2 | 2012 | 615 | 0.160 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2021 | 494 | 0.160 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 1999 | 421 | 0.160 |
Why?
|
| Image-Guided Biopsy | 2 | 2018 | 327 | 0.160 |
Why?
|
| Sertoli Cells | 1 | 1998 | 150 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2015 | 986 | 0.150 |
Why?
|
| Parotid Neoplasms | 1 | 1998 | 148 | 0.150 |
Why?
|
| Mutation | 4 | 2014 | 15179 | 0.150 |
Why?
|
| omega-N-Methylarginine | 1 | 2016 | 34 | 0.150 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 1998 | 170 | 0.150 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1996 | 25 | 0.150 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 1165 | 0.150 |
Why?
|
| False Negative Reactions | 3 | 2016 | 275 | 0.140 |
Why?
|
| Cystadenoma, Papillary | 1 | 1995 | 5 | 0.140 |
Why?
|
| Calcinosis | 2 | 2010 | 423 | 0.140 |
Why?
|
| Bevacizumab | 2 | 2017 | 938 | 0.140 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 81 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 261 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 2 | 1999 | 2326 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6207 | 0.140 |
Why?
|
| Myasthenia Gravis | 1 | 1997 | 99 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2012 | 4892 | 0.130 |
Why?
|
| Cell Dedifferentiation | 1 | 2016 | 96 | 0.130 |
Why?
|
| Epididymis | 1 | 1995 | 68 | 0.130 |
Why?
|
| Thymus Gland | 1 | 1997 | 294 | 0.130 |
Why?
|
| Necrosis | 2 | 2012 | 580 | 0.130 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1995 | 47 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 15862 | 0.130 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1995 | 115 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2011 | 10001 | 0.130 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 1656 | 0.120 |
Why?
|
| Coloring Agents | 2 | 2009 | 234 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 1546 | 0.120 |
Why?
|
| Adenocarcinoma | 5 | 2009 | 7789 | 0.120 |
Why?
|
| Kidney Neoplasms | 2 | 1999 | 3022 | 0.120 |
Why?
|
| GATA3 Transcription Factor | 1 | 2015 | 146 | 0.120 |
Why?
|
| Serum Albumin | 2 | 1992 | 257 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 4988 | 0.120 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2013 | 33 | 0.120 |
Why?
|
| Hematoxylin | 1 | 2013 | 34 | 0.120 |
Why?
|
| Collagen | 2 | 2000 | 752 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1997 | 261 | 0.120 |
Why?
|
| Papilloma | 1 | 2013 | 74 | 0.120 |
Why?
|
| Flow Cytometry | 3 | 2009 | 3033 | 0.120 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1998 | 489 | 0.120 |
Why?
|
| Adenoma | 1 | 1998 | 716 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 878 | 0.110 |
Why?
|
| Nitric Oxide Synthase | 1 | 2014 | 314 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2013 | 185 | 0.110 |
Why?
|
| Survival Rate | 9 | 2020 | 12221 | 0.110 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1022 | 0.110 |
Why?
|
| Teratoma | 1 | 1995 | 236 | 0.110 |
Why?
|
| Mesoderm | 1 | 2015 | 404 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 176 | 0.110 |
Why?
|
| Prostatectomy | 1 | 1997 | 962 | 0.110 |
Why?
|
| Paget's Disease, Mammary | 1 | 2012 | 41 | 0.110 |
Why?
|
| Chemotactic Factors | 1 | 1992 | 42 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 8873 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 4971 | 0.110 |
Why?
|
| Microscopy | 1 | 2013 | 182 | 0.110 |
Why?
|
| Optical Imaging | 1 | 2013 | 157 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 612 | 0.100 |
Why?
|
| Lung Neoplasms | 7 | 2014 | 11538 | 0.100 |
Why?
|
| DNA | 2 | 1997 | 2693 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1995 | 551 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2018 | 2292 | 0.100 |
Why?
|
| Mucocele | 1 | 2011 | 22 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2021 | 5270 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 1879 | 0.100 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2010 | 22 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 550 | 0.100 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 14551 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2003 | 1823 | 0.090 |
Why?
|
| Retrospective Studies | 11 | 2020 | 37905 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 6009 | 0.090 |
Why?
|
| BRCA2 Protein | 1 | 2012 | 358 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2018 | 3890 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2016 | 1959 | 0.090 |
Why?
|
| Lymphoma | 1 | 1998 | 1467 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 1998 | 1350 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 592 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 2016 | 5395 | 0.090 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 229 | 0.090 |
Why?
|
| Histiocytosis, Sinus | 1 | 2010 | 86 | 0.090 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 3230 | 0.080 |
Why?
|
| Chondrogenesis | 1 | 2009 | 67 | 0.080 |
Why?
|
| Cross-Linking Reagents | 1 | 2009 | 153 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 709 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 1991 | 333 | 0.080 |
Why?
|
| Cell Communication | 1 | 1991 | 509 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2005 | 5319 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 318 | 0.080 |
Why?
|
| Cell Movement | 3 | 2016 | 2466 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 591 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 14289 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1999 | 1833 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2009 | 330 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2009 | 153 | 0.080 |
Why?
|
| DNA Methylation | 3 | 2003 | 2669 | 0.080 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 1162 | 0.080 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 14889 | 0.080 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 760 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 135 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 793 | 0.070 |
Why?
|
| Ploidies | 2 | 1997 | 248 | 0.070 |
Why?
|
| Neutrophils | 1 | 1991 | 835 | 0.070 |
Why?
|
| Trastuzumab | 1 | 2009 | 696 | 0.070 |
Why?
|
| Young Adult | 6 | 2016 | 21445 | 0.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 205 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 1990 | 862 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 600 | 0.070 |
Why?
|
| Receptor Cross-Talk | 1 | 2006 | 79 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 2283 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1998 | 2341 | 0.070 |
Why?
|
| Keratins | 1 | 2007 | 330 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2005 | 6150 | 0.070 |
Why?
|
| Cattle | 3 | 1992 | 783 | 0.070 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2007 | 192 | 0.070 |
Why?
|
| Genes, ras | 1 | 2009 | 667 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 726 | 0.070 |
Why?
|
| Cytoplasm | 2 | 1998 | 652 | 0.070 |
Why?
|
| DNA, Neoplasm | 4 | 2009 | 1910 | 0.070 |
Why?
|
| Heart Neoplasms | 1 | 2007 | 214 | 0.070 |
Why?
|
| Epithelium | 1 | 2007 | 720 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2005 | 9180 | 0.060 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 634 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2009 | 3536 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2003 | 1064 | 0.060 |
Why?
|
| Patient Selection | 2 | 2011 | 2055 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 3101 | 0.060 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2009 | 486 | 0.060 |
Why?
|
| In Vitro Techniques | 3 | 1992 | 1618 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2010 | 7702 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2005 | 274 | 0.060 |
Why?
|
| Staining and Labeling | 2 | 2015 | 429 | 0.060 |
Why?
|
| Integrin beta4 | 1 | 2004 | 22 | 0.060 |
Why?
|
| Risk | 1 | 2009 | 1972 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 2231 | 0.060 |
Why?
|
| Fibronectins | 2 | 2001 | 197 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2003 | 115 | 0.060 |
Why?
|
| Time Factors | 4 | 2014 | 12926 | 0.060 |
Why?
|
| Male | 14 | 2011 | 123000 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 2054 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2005 | 842 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 577 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 615 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2016 | 7226 | 0.050 |
Why?
|
| Membrane Transport Proteins | 2 | 2015 | 244 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 1519 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 4367 | 0.050 |
Why?
|
| Animals | 8 | 2021 | 59536 | 0.050 |
Why?
|
| Endotoxins | 2 | 1992 | 96 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 2359 | 0.050 |
Why?
|
| Receptors, Thrombin | 1 | 2001 | 23 | 0.050 |
Why?
|
| Biopsy | 3 | 2010 | 3443 | 0.050 |
Why?
|
| Sirolimus | 2 | 2017 | 814 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 660 | 0.050 |
Why?
|
| Glycation End Products, Advanced | 2 | 1992 | 31 | 0.050 |
Why?
|
| Serum Albumin, Bovine | 2 | 1992 | 83 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 208 | 0.050 |
Why?
|
| Glycosylation | 2 | 1992 | 213 | 0.050 |
Why?
|
| Recurrence | 1 | 2009 | 4758 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 1997 | 5767 | 0.050 |
Why?
|
| Models, Biological | 2 | 2007 | 3254 | 0.050 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2001 | 129 | 0.050 |
Why?
|
| Carcinoid Tumor | 2 | 2001 | 280 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2015 | 521 | 0.050 |
Why?
|
| Chondromatosis, Synovial | 1 | 1999 | 5 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2018 | 12873 | 0.050 |
Why?
|
| Temporomandibular Joint | 1 | 1999 | 24 | 0.050 |
Why?
|
| Laminin | 1 | 2000 | 194 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 2 | 2001 | 408 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 338 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 8865 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 2216 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 178 | 0.040 |
Why?
|
| Cell Separation | 2 | 1992 | 612 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 492 | 0.040 |
Why?
|
| Inflammation | 1 | 2009 | 2522 | 0.040 |
Why?
|
| Observer Variation | 2 | 2014 | 671 | 0.040 |
Why?
|
| Vacuoles | 1 | 1998 | 51 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 332 | 0.040 |
Why?
|
| Cystadenoma | 1 | 1998 | 26 | 0.040 |
Why?
|
| Tight Junctions | 1 | 1998 | 56 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 2508 | 0.040 |
Why?
|
| Neoplasms | 2 | 2006 | 15193 | 0.040 |
Why?
|
| Mitotic Index | 1 | 1998 | 162 | 0.040 |
Why?
|
| Histiocytosis | 1 | 1998 | 54 | 0.040 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 1998 | 103 | 0.040 |
Why?
|
| Cysts | 1 | 2000 | 197 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1998 | 119 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2021 | 419 | 0.040 |
Why?
|
| Adenoma, Oxyphilic | 1 | 1998 | 82 | 0.040 |
Why?
|
| Kinetics | 2 | 1992 | 2049 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 470 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 3251 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 2021 | 533 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 3 | 2003 | 98 | 0.040 |
Why?
|
| Leiomyoma | 1 | 1999 | 145 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 4298 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 3203 | 0.040 |
Why?
|
| Pulmonary Artery | 2 | 1992 | 499 | 0.040 |
Why?
|
| Ubiquitin C | 1 | 2016 | 3 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 34 | 0.040 |
Why?
|
| Receptors, Very Late Antigen | 1 | 1996 | 8 | 0.040 |
Why?
|
| Nitrates | 1 | 2016 | 43 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1999 | 829 | 0.040 |
Why?
|
| Nitrites | 1 | 2016 | 61 | 0.040 |
Why?
|
| Integrin alpha4beta1 | 1 | 1996 | 45 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2009 | 5159 | 0.040 |
Why?
|
| Adenosine Deaminase | 1 | 2016 | 94 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 1998 | 666 | 0.040 |
Why?
|
| Liposarcoma | 1 | 1998 | 214 | 0.040 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 25 | 0.040 |
Why?
|
| Mice | 4 | 2021 | 34495 | 0.040 |
Why?
|
| Lymphatic Diseases | 1 | 1997 | 128 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2016 | 69 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2001 | 713 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 223 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2016 | 222 | 0.030 |
Why?
|
| Sacrococcygeal Region | 1 | 1995 | 37 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.030 |
Why?
|
| Glucose | 2 | 1991 | 1248 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2011 | 1620 | 0.030 |
Why?
|
| Autopsy | 1 | 1995 | 173 | 0.030 |
Why?
|
| Everolimus | 1 | 2017 | 415 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 2045 | 0.030 |
Why?
|
| Algorithms | 1 | 2006 | 3890 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2011 | 4078 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 733 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2012 | 32848 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1998 | 1681 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 430 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 4143 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.030 |
Why?
|
| Smoking | 1 | 2003 | 2440 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 771 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 1995 | 245 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 4638 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3821 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2013 | 134 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2011 | 1529 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 1991 | 5637 | 0.030 |
Why?
|
| Disease Progression | 2 | 2004 | 6682 | 0.030 |
Why?
|
| Dermis | 1 | 2012 | 65 | 0.030 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2003 | 69 | 0.030 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2003 | 69 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 823 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 3639 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1992 | 157 | 0.030 |
Why?
|
| Streptozocin | 1 | 1991 | 75 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2011 | 79 | 0.030 |
Why?
|
| Chromogranin A | 1 | 2011 | 65 | 0.020 |
Why?
|
| Hypertonic Solutions | 1 | 1991 | 31 | 0.020 |
Why?
|
| Hypoxia | 1 | 2014 | 443 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 2074 | 0.020 |
Why?
|
| Mannitol | 1 | 1991 | 54 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1991 | 156 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 3719 | 0.020 |
Why?
|
| Glutathione Transferase | 2 | 2003 | 359 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 1991 | 122 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2003 | 365 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 984 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1992 | 549 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 651 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 1990 | 82 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 4821 | 0.020 |
Why?
|
| Microcirculation | 1 | 1991 | 200 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 644 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1121 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1995 | 787 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2003 | 476 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 1869 | 0.020 |
Why?
|
| Giant Cells | 1 | 2010 | 69 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1991 | 224 | 0.020 |
Why?
|
| Isoenzymes | 2 | 2003 | 614 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 172 | 0.020 |
Why?
|
| Base Sequence | 1 | 1995 | 4917 | 0.020 |
Why?
|
| Cadherins | 2 | 2003 | 660 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 6089 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2015 | 1996 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 7551 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2009 | 286 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Incidence | 1 | 1997 | 5673 | 0.020 |
Why?
|
| Premenopause | 1 | 2007 | 131 | 0.020 |
Why?
|
| Retina | 1 | 1991 | 532 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2007 | 4804 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 118 | 0.020 |
Why?
|
| Epirubicin | 1 | 2007 | 157 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2010 | 731 | 0.020 |
Why?
|
| United States | 2 | 2020 | 15433 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 691 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 3552 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 2390 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 3869 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 2291 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.020 |
Why?
|
| ras Proteins | 1 | 2009 | 770 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2007 | 351 | 0.020 |
Why?
|
| COP9 Signalosome Complex | 1 | 2003 | 72 | 0.010 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2004 | 74 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2004 | 95 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 690 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 7222 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1991 | 4938 | 0.010 |
Why?
|
| Contrast Media | 1 | 2010 | 1472 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 2403 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 462 | 0.010 |
Why?
|
| Taiwan | 1 | 2003 | 93 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2003 | 287 | 0.010 |
Why?
|
| Rats | 1 | 1991 | 6086 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2007 | 1944 | 0.010 |
Why?
|
| Japan | 1 | 2003 | 227 | 0.010 |
Why?
|
| Australia | 1 | 2003 | 225 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1331 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2005 | 1053 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 8223 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2003 | 256 | 0.010 |
Why?
|
| Receptor, PAR-1 | 1 | 2001 | 33 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4757 | 0.010 |
Why?
|
| Melanoma | 1 | 1998 | 5317 | 0.010 |
Why?
|
| Bronchial Neoplasms | 1 | 2001 | 79 | 0.010 |
Why?
|
| Thrombin | 1 | 2001 | 99 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2001 | 143 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 3154 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2001 | 256 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2001 | 259 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 360 | 0.010 |
Why?
|
| Mitochondria | 1 | 2007 | 1282 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 2488 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 3001 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2232 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 575 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 602 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 6311 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2001 | 584 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 1265 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 2489 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 9244 | 0.010 |
Why?
|
| Risk Factors | 2 | 2004 | 17523 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 31252 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 5114 | 0.010 |
Why?
|
| Proteins | 1 | 2001 | 1963 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 7591 | 0.010 |
Why?
|